Breast Atypia as a Biomarker of Risk
Purpose of Review
Provide a summary of available evidence on breast atypia as a biomarker of risk.
With an increase in independent studies on atypical hyperplasia (AH), knowledge has advanced recently regarding its subsequent associated breast cancer risk. For women with AH, absolute risk can be estimated generally as ~ 1% per year, and a greater extent of disease appears to further increase risk. Although both breasts are at increased risk, the risk is higher for the ipsilateral breast. In women with AH, a family history of breast cancer does not confer significantly increased risk. Risk is similar for atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), with some reports suggesting mildly higher risk for ALH. Prevention medications reduce breast cancer risk by ~ 70% in AH.
Women with AH should be counseled on their increased risk and the option of prevention medication.
KeywordsAtypical hyperplasia Breast Risk Risk prediction Breast cancer Biomarker
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211–7. https://doi.org/10.1158/1940-6207.CAPR-13-0222.CrossRefGoogle Scholar
- 8.• Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer. 2018;124(3):459–65. https://doi.org/10.1002/cncr.31061 This paper reports breast cancer risk in a modern cohort of women with high-risk histologic findings that were diagnosed percutaneously, confirming breast cancer risk similar to women with high-risk lesions diagnosed by surgical excision. CrossRefGoogle Scholar
- 9.• Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 2017;3(1):36–41. https://doi.org/10.1001/jamaoncol.2016.3022 In this multicenter screening mammography cohort, risk of invasive breast cancer in women with ADH appears lower than estimates from cohorts of women undergoing breast biopsy. CrossRefGoogle Scholar
- 11.Boughey JC, Hartmann LC, Anderson SS, Degnim AC, Vierkant RA, Reynolds CA, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28(22):3591–6. https://doi.org/10.1200/JCO.2010.28.0784.CrossRefGoogle Scholar
- 13.Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomark Prev. 1997;6(5):297–301.Google Scholar
- 15.•• Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: an update from the Nurses’ Health Studies. Cancer. 2016;122(4):515–20. https://doi.org/10.1002/cncr.29775 In the Nurses’ Health Study, there was no significant association of the extent of atypical hyperplasia of with subsequent breast cancer risk. CrossRefGoogle Scholar
- 17.Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses’ Health Study. Cancer. 2006;107(6):1240–7. https://doi.org/10.1002/cncr.22136.CrossRefGoogle Scholar
- 23.•• Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, et al. Model for predicting breast cancer risk in women with atypical hyperplasia. J Clin Oncol. 2018;36(18):1840–6. https://doi.org/10.1200/JCO.2017.75.9480 This is a new breast cancer risk prediction model specifically designed for women with atypical hyperplasia that was developed in the Mayo Clinic Benign Breast Disease Cohort and validated in the Nashville Breast Cohort. CrossRefGoogle Scholar
- 25.•• Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer. 2016;122(19):2971–8. https://doi.org/10.1002/cncr.30153 In the Nashville and Mayo Clinic Benign Breast Disease Cohorts, the number of foci of atypical hyperplasia is significantly associated with subsequent breast cancer risk, with increasing risk observed in women with more foci of atypia. CrossRefGoogle Scholar
- 26.Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35(10):1061–9. https://doi.org/10.1200/JCO.2016.69.4406.CrossRefGoogle Scholar